Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 eu ...

"According to a new research report titled Styrene Maleic Anhydride (SMA) Copolymer Market Global Industry Perspective, Comprehensive Analysis And Forecast by 2025 – 2032 The report delivers detailed ...

Problems with chemical messengers like dopamine were tied to posture issues in SMA in a mouse study, but levodopa therapy may ease symptoms.

FuelCell Energy FCEL is trading below its 50-day and 200-day simple moving average (SMA), signaling a bearish trend. FCEL ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

EUR/USD remains under pressure, with key support levels at 1.0176 (year-to-date low on January 13) and the parity level at ...

Silver price recovers some ground and trades with gains of 0.91% yet it has failed to clear key resistance at the 100-day ...

The company argues that SMA costs per child range from 2.5 million ... framework” and is reimbursement expected to begin in Germany shortly. European approval is based on the completed phase ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...